Myelofibrosis Specialty Channel

Myelofibrosis

Specialty Channel

News

Fedratinib Demonstrates Promising Efficacy for Second-Line Treatment of Myelofibrosis

10/31/2024

According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.

According to a phase 3 trial,...

10/31/2024

Oncology

Quiz

Use of Luspatercept for Patients With Myelofibrosis-Associated Anemia

10/16/2024

True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...

True or False: According to...

10/16/2024

Oncology

Quiz

Low-Dose Subcutaneous Decitabine Treatment for Patients With MF

10/11/2024

True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...

True or False: According to...

10/11/2024

Oncology

News

Momelotinib Demonstrates Improved Spleen and Symptom Requirements Among Subgroup of Patients With JAK Inhibitor-Naive Myelofibrosis

10/10/2024

Amber Denham ;

Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.

Momelotinib was well-tolerated,...

10/10/2024

Oncology

News

Luspatercept Improves Anemia Among Patients With Myelofibrosis With or Without Transfusion Dependence

10/04/2024

Amber Denham ;

Luspatercept improved anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell transfusion dependence and concurrent JAK inhibitor treatment, concluded a recent phase 2 trial.

Luspatercept improved anemia and...

10/04/2024

Oncology

News

Investigating Low-Dose Subcutaneous Decitabine Treatment for Patients With Myelofibrosis

10/02/2024

Amber Denham ;

According to a prospective phase 2 trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained declines in circulating CD34+ cell counts were associated with response to hypomethylating agent decitabine treatment for...

According to a prospective phase...

10/02/2024

Oncology

News

Sovleplenib Demonstrates Clinically Meaningful Response Among Patients With Chronic Primary Immune Thrombocytopenia

08/29/2024

Amber Denham ;

Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.

Sovleplenib, a novel spleen...

08/29/2024

Oncology

Quiz

Efficacy of Zilurgisertib Alone or Combined With Ruxolitinib in Myelofibrosis

08/22/2024

True or False: According to phase 1/2 results from an ongoing open-label, dose-escalation/expansion study presented at the 2024 European Hematology Association Meeting, zilurgisertib treatment as monotherapy or in combination with ruxolitinib...

True or False: According to...

08/22/2024

Oncology

Videos

Innovative Developments in Myelofibrosis Treatment Options

08/16/2024

Prithviraj Bose, MD, discusses novel developments and future potential in myelofibrosis treatment, highlighting BET inhibitors, PIM kinase inhibitors, and phase 3 trial data on imetelstat, and luspatercept.

Prithviraj Bose, MD, discusses...

08/16/2024

Oncology

News

Triple-Negative Myelofibrosis Associated With Decreased Survival, Aggressive Clinical Behavior and Shorter Duration of Response to Ruxolitinib

08/14/2024

Amber Denham ;

Triple-negative myelofibrosis was found to be continually associated with decreased survival in addition to enhanced aggressive behavior with higher rates of leukemic transformation as well as a shorter duration of response to ruxolitinib,...

Triple-negative myelofibrosis...

08/14/2024

Oncology

Quiz

Examining the Efficacy of Azacitidine Plus Ruxolitinib in Myelofibrosis Treatment

07/03/2024

Oncology

News

Conference Coverage

Azacitidine Plus Ruxolitinib Demonstrates ‘Promising’ Efficacy in Myelofibrosis

05/31/2024

Amber Denham

Long-term follow-up results from a phase 2 trial highlight the promising efficacy of azacitidine in combination with ruxolitinib for patients with myelofibrosis.

Long-term follow-up results from...

05/31/2024

Oncology

Conference Coverage

Pelabresib Plus Ruxolitinib Reduces Splenomegaly, Improves Anemia Among JAK-Inhibitor-Naive Patients With Myelofibrosis

05/30/2024

Amber Denham

Pelabresib plus ruxolitinib significantly reduced splenomegaly and improved anemia and bone marrow fibrosis compared with placebo plus ruxolitinib among JAK-inhibitor-treatment-naïve patients with myelofibrosis, according to updated phase 3...

Pelabresib plus ruxolitinib...

05/30/2024

Oncology

News

Rusfertide Treatment Strengthens Response and Decreases Erythrocytosis Among Patients With Polycythemia Vera

03/22/2024

Jordan Kadish

According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.

According to findings from the...

03/22/2024

Oncology

News

Evaluating Clinically Meaningful Symptom Benefits and Symptom Change Threshold Among Patients With Myelofibrosis Treated With Momelotinib

02/27/2024

Jordan Kadish

Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that analyzed the appropriateness of the symptom change threshold used in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.

Momelotinib displayed clinically...

02/27/2024

Oncology

News

Addition of Parsaclisib to Ruxolitinib Decreases Spleen Volume and Improves Symptom Scores Among Patients With Myelofibrosis

02/23/2024

Jordan Kadish

The addition of parsaclisib to ruxolitinib treatment decreased spleen volume, improved symptom scores, and demonstrated acceptable safety among patients with primary or secondary myelofibrosis, according to a phase 2 study.

The addition of parsaclisib to...

02/23/2024

Oncology

News

Early Implementation of Increased Dose of Ropeginterferon Driven by Phlebotomy Need Improves Efficacy Among Patients With Low-Risk Polycythemia Vera

02/08/2024

Mellanie True Hills ;

Increasing the dose of ropeginterferon and implementing it earlier driven by high phlebotomy needs improved efficacy outcomes among patients with low-risk polycythemia vera, according to a phase 2 study.

Increasing the dose of...

02/08/2024

Oncology

News

Ruxolitinib Strengthens Survival Outcomes Among High-Risk Patients With Myelofibrosis

01/22/2024

Mellanie True Hills ;

Ruxolitinib treatment strengthened survival outcomes among high-risk patients with myelofibrosis, according to findings from a population-based retrospective study.

Ruxolitinib treatment...

01/22/2024

Oncology

News

Ropeginterferon Alfa-2B Demonstrates Efficacy Among High-Risk Patients With Philadelphia-Negative Myeloproliferative Neoplasms

01/22/2024

Mellanie True Hills ;

A retrospective observational study showed that ropeginterferon alfa-2b demonstrated efficacy among high-risk patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

A retrospective observational...

01/22/2024

Oncology

News

Pelabresib Plus Ruxolitinib Shows Clinical Benefit Among JAK-Naïve Patients With Myelofibrosis

01/05/2024

Mellanie True Hills ;

Results from the phase 3 MANIFEST-2 study demonstrated that combining pelabresib and ruxolitinib yielded clinical activity among patients with JAK-naïve myelofibrosis.

Results from the phase 3...

01/05/2024

Oncology

News

Inflammatory Comorbidities as Prognostic Factors Among Younger Patients With Myelofibrosis

01/05/2024

Mellanie True Hills ;

Retrospective analysis findings indicated that inflammatory comorbidities were correlated with progression of disease risk among younger patients with myelofibrosis.

Retrospective analysis findings...

01/05/2024

Oncology

Interactive Features

Quiz

Examining the Efficacy of Azacitidine Plus Ruxolitinib in Myelofibrosis Treatment

07/03/2024

Oncology

Quiz

Effect of Momelotinib on Symptom Benefits Among Patients With Myelofibrosis

02/28/2024

True or False: Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that demonstrated insight into the appropriateness of the symptom change threshold used in the phase 3...

True or False: Momelotinib...

02/28/2024

Oncology

Quiz

Parsaclisib Plus Stable-Dose Ruxolitinib for Myelofibrosis

02/27/2024

The addition of parsaclisib to stable-dose ruxolitinib treatment ___ splenomegaly and ___ symptom scores among patients with primary or secondary myelofibrosis who did not have optimal responses to ruxolitinib alone, according to findings...

The addition of parsaclisib to...

02/27/2024

Oncology

Quiz

5-Year Survival and Efficacy of Ropeginterferon for Low-Risk Polycythemia Vera

02/13/2024

What was the main finding of a phase 2 trial on the 5-year survival and efficacy of ropeginterferon among patients with low-risk polycythemia vera?

What was the main finding of a...

02/13/2024

Oncology

Quiz

Survival Outcomes Among High-Risk Patients With MF Treated With Ruxolitinib

01/31/2024

What was the key finding of a population-based retrospective cohort study analyzing the outcomes of higher-risk patients with myelofibrosis treated with ruxolitinib in an unselected real-world population?

What was the key finding of a...

01/31/2024

Oncology

Quiz

Treating High-Risk Philadelphia-Negative MPNs With Ropeginterferon Alfa-2B

01/31/2024

True or False: Findings from a retrospective observational study show that ropeginterferon alfa-2b demonstrated high response rates and tolerable safety among young high-risk patients with Philadelphia chromosome-negative myeloproliferative...

True or False: Findings from a...

01/31/2024

Oncology

Quiz

Ruxolitinib for Elderly JAK Inhibitor-Naïve Patients With Myelofibrosis

01/16/2024

True or False: Interim results from the phase 4 JAKoMO trial indicated that ruxolitinib demonstrated safety and efficacy among elderly Janus kinase (JAK) inhibitor-naïve patients with myelofibrosis in the real-world setting.

True or False: Interim results...

01/16/2024

Oncology

Quiz

Treating JAK-Naive Patients With Myelofibrosis With Pelabresib Plus Ruxolitinib

01/05/2024

What was the key finding of the MANIFEST-2 trial on the combination of pelabresib and ruxolitinib among patients with JAK-naïve myelofibrosis?

What was the key finding of the...

01/05/2024

Oncology

Quiz

Impact of Inflammatory Comorbidities on Myelofibrosis Disease Risk

01/05/2024

True or False: According to a retrospective analysis of younger patients with myelofibrosis (MF), inflammatory comorbidities were correlated with increased disease risk and decreased survival.

True or False: According to a...

01/05/2024

Oncology

Quiz

Treating Myelofibrosis With Pacritinib

12/06/2023

True or False: Pacritinib demonstrated consistent efficacy for spleen and symptom response among patients with myelofibrosis (MF), regardless of cytopenias.

True or False: Pacritinib...

12/06/2023

Oncology

Recent News

News

Rusfertide Treatment Strengthens Response and Decreases Erythrocytosis Among Patients With Polycythemia Vera

03/22/2024

Jordan Kadish

According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.

According to findings from the...

03/22/2024

Oncology

News

Evaluating Clinically Meaningful Symptom Benefits and Symptom Change Threshold Among Patients With Myelofibrosis Treated With Momelotinib

02/27/2024

Jordan Kadish

Momelotinib displayed clinically...

02/27/2024

Oncology

News

Addition of Parsaclisib to Ruxolitinib Decreases Spleen Volume and Improves Symptom Scores Among Patients With Myelofibrosis

02/23/2024

Jordan Kadish

The addition of parsaclisib to...

02/23/2024

Oncology

News

Early Implementation of Increased Dose of Ropeginterferon Driven by Phlebotomy Need Improves Efficacy Among Patients With Low-Risk Polycythemia Vera

02/08/2024

Mellanie True Hills ;

Increasing the dose of...

02/08/2024

Oncology

News

Ruxolitinib Strengthens Survival Outcomes Among High-Risk Patients With Myelofibrosis

01/22/2024

Mellanie True Hills ;

Ruxolitinib treatment strengthened survival outcomes among high-risk patients with myelofibrosis, according to findings from a population-based retrospective study.

Ruxolitinib treatment...

01/22/2024

Oncology

News

Ropeginterferon Alfa-2B Demonstrates Efficacy Among High-Risk Patients With Philadelphia-Negative Myeloproliferative Neoplasms

01/22/2024

Mellanie True Hills ;

A retrospective observational study showed that ropeginterferon alfa-2b demonstrated efficacy among high-risk patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

A retrospective observational...

01/22/2024

Oncology

News

Pelabresib Plus Ruxolitinib Shows Clinical Benefit Among JAK-Naïve Patients With Myelofibrosis

01/05/2024

Mellanie True Hills ;

Results from the phase 3 MANIFEST-2 study demonstrated that combining pelabresib and ruxolitinib yielded clinical activity among patients with JAK-naïve myelofibrosis.

Results from the phase 3...

01/05/2024

Oncology

News

Inflammatory Comorbidities as Prognostic Factors Among Younger Patients With Myelofibrosis

01/05/2024

Mellanie True Hills ;

Retrospective analysis findings indicated that inflammatory comorbidities were correlated with progression of disease risk among younger patients with myelofibrosis.

Retrospective analysis findings...

01/05/2024

Oncology

News

Ruxolitinib Exhibits Safety, Efficacy Among Elderly Patients With Therapy-Naïve Myelofibrosis

11/20/2023

Amber Denham ;

Real-world results from a phase 4 study demonstrate that among elderly patients with therapy-naïve myelofibrosis, ruxolitinib treatment yielded safety and efficacy.

Real-world results from a phase...

11/20/2023

Oncology

News

Momelotinib Yields Substantial Symptom Benefits Among Patients With Myelofibrosis

11/08/2023

Amber Denham ;

Patient-reported outcomes from the phase 3 MOMENTUM trial demonstrated that momelotinib provided rapid and durable response benefits among anemic and symptomatic patients with myelofibrosis (MF).

Patient-reported outcomes from...

11/08/2023

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology